Anti-AP002347.1 functional antibody

Anti-AP002347.1 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to AP002347.1/ products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1682-Ab-1/ GM-Tg-hg-SE1682-Ab-2Anti-Human AP002347.1 monoclonal antibodyHuman
GM-Tg-rg-SE1682-Ab-1/ GM-Tg-rg-SE1682-Ab-2Anti-Rat AP002347.1 monoclonal antibodyRat
GM-Tg-mg-SE1682-Ab-1/ GM-Tg-mg-SE1682-Ab-2Anti-Mouse AP002347.1 monoclonal antibodyMouse
GM-Tg-cynog-SE1682-Ab-1/ GM-Tg-cynog-SE1682-Ab-2Anti-Cynomolgus/ Rhesus macaque AP002347.1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1682-Ab-1/ GM-Tg-felg-SE1682-Ab-2Anti-Feline AP002347.1 monoclonal antibodyFeline
GM-Tg-cang-SE1682-Ab-1/ GM-Tg-cang-SE1682-Ab-2Anti-Canine AP002347.1 monoclonal antibodyCanine
GM-Tg-bovg-SE1682-Ab-1/ GM-Tg-bovg-SE1682-Ab-2Anti-Bovine AP002347.1 monoclonal antibodyBovine
GM-Tg-equg-SE1682-Ab-1/ GM-Tg-equg-SE1682-Ab-2Anti-Equine AP002347.1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1682-Ab-1/ GM-Tg-hg-SE1682-Ab-2; GM-Tg-rg-SE1682-Ab-1/ GM-Tg-rg-SE1682-Ab-2;
GM-Tg-mg-SE1682-Ab-1/ GM-Tg-mg-SE1682-Ab-2; GM-Tg-cynog-SE1682-Ab-1/ GM-Tg-cynog-SE1682-Ab-2;
GM-Tg-felg-SE1682-Ab-1/ GM-Tg-felg-SE1682-Ab-2; GM-Tg-cang-SE1682-Ab-1/ GM-Tg-cang-SE1682-Ab-2;
GM-Tg-bovg-SE1682-Ab-1/ GM-Tg-bovg-SE1682-Ab-2; GM-Tg-equg-SE1682-Ab-1/ GM-Tg-equg-SE1682-Ab-2
Products NameAnti-AP002347.1 monoclonal antibody
Formatmab
Target NameAP002347.1
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-AP002347.1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1682-Ag-1Recombinant multi-species AP002347.1 protein


    Target information

    Target IDGM-SE1682
    Target NameAP002347.1
    Gene IDN/A
    Gene Symbol and Synonyms
    Uniprot AccessionN/A
    Uniprot Entry Name
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000285231
    Target ClassificationN/A

    The target: AP002347.1, gene name: , also named as . .



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.